INOVIO announced initiation of phase 2/3 clinical trial for COVID-19 DNA vaccine candidate, INO-4800
On Nov. 16, 2020, INOVIO announced that it had received clearance from the the U.S. Food & Drug…
On Nov. 16, 2020, INOVIO announced that it had received clearance from the the U.S. Food & Drug…
On Nov. 16, 2020, Moderna announced that the European Medicines Agency (EMA) human medicines committee (CHMP) had started…
On Nov. 15, 2020, Johnson & Johnson announced that it continued to enroll and vaccinate study participants for…
On Nov. 15, 2020, an independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of…
On Nov. 13, 2020, Moderna announced that Swissmedic had started a rolling review of mRNA-1273, the Company’s vaccine…
On Nov. 12, 2020, CureVac announced that its mRNA-based COVID-19 vaccine candidate, CVnCoV, remained stable and within defined…
On Nov. 12, 2020, the Bill & Melinda Gates Foundation announced new commitments totaling $70 million to global…
On Nov. 12, 2020 Vaxart announced additional results from its Hamster Challenge Study. The study evaluated Vaxartï¾’s recombinant…
On Nov. 11, 2020, Sorrento Therapeutics announced that it was filing an investigational new drug application (IND) for…
On Nov. 11, 2020, the Serum Institute of India (SII) and Indian Council of Medical Research (ICMR) announced…
On Nov. 11, 2020, Moderna announced that it had completed case accrual for the first interim analysis of…
On Nov. 11, 2020, Pfizer and BioNTech announced that they had reached an agreement with the European Commission…
On Nov. 19, 2020, Medigen Vaccine Biologics and BlueWillow Biologics announced a partnership to develop S-2P-NE-01, a nasal…
On Nov. 10, 2020, ImmunityBio and NantKwest, a clinical-stage, natural killer cell-based therapeutics company, announced they had administered…
On Nov. 10, 2020, Altimmune announced an agreement with Lonza for the manufacturing of AdCOVIDï¾™, Altimmuneï¾’s next-generation, single-dose…
On Nov. 9, 2020, Pfizer and BioNTech announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 had demonstrated evidence…
On Nov. 9, 2020, the Fred Hutchinson Cancer Research Center announced the start of volunteer enrollment for a…
On Nov. 8, 2020, ImmunityBio announced positive study results for their human Ad5 (hAd5) COVID-19 vaccine candidate, which…
On Nov. 4, 2020, Novavax announced the signing of a non-binding Heads of Terms document with the Australian…
On Nov. 3, 2020, Medigen Vaccine Biologics (MVC) and the National Institute of Hygiene and Epidemiology (NIHE), a…
On Nov. 2, 2020, Novavax announced the expansion of its Maryland campus to accommodate the company’s rapid growth…
On Nov. 2, 2020, CureVac announced positive interim data from its ongoing Phase 1 dose-escalation study evaluating the…
On Oct. 30, 2020, Kaiser Permanente Washington Health Research Institute (KPWHRI) announced enrollment of volunteers in a phase…
On Oct. 30, 2020, the University of Oxford announced that Kenya had joined the global efforts in search…
On Oct. 30, 2020, Icosavax announced the launch of the companyï¾’s COVID-19 vaccine program with preclinical data on…
On Oct. 29, 2020, Takeda Pharmaceutical announced that it would import and distribute 50 million doses of Moderna’s…
On Oct. 27, 2020, Moderna announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
On Oct. 27, 2020, Novavax announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19…
On Oct. 26, 2020, Moderna announced a supply agreement with the Ministry of Public Health of Qatar for…
On Oct. 23, 2020, Entos Pharmaceuticals announced it was receiving advisory services and funding of up to $5…